Pfizer Inc. is licensing its experimental Covid-19 antiviral to a global health organization in an effort to make the pill more readily available to people in low- and middle-income countries.

Under the licensing agreement, the United Nations-backed Medicines Patent Pool will work with other drugmakers to manufacture the pill for use in 95 countries, including in sub-Saharan Africa, Pfizer and the nonprofit said Tuesday.

This post first appeared on wsj.com

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Lollapalooza cancels DaBaby performance after homophobic remarks

The Lollapalooza music festival cancelled DaBaby’s Sunday night performance in response to…

North African Countries Snap Up Russian Oil Products Shunned by West

Business Some Russian cargo is being exported back to Europe, analysts suspect…

Utah grief author accused of poisoning her husband sued for over $13M by his sister

A lawsuit against a Utah woman who wrote a children’s book about…

China Orders Tech Giants to Unbundle Financial Services

SINGAPORE—In recent years, China’s technology giants have turned consumers’ embrace of mobile…